Analysts Set Encompass Health Corporation (NYSE:EHC) PT at $143.29

Shares of Encompass Health Corporation (NYSE:EHC) have been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $143.2857.

Several equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Encompass Health from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Barclays raised their target price on shares of Encompass Health from $150.00 to $153.00 and gave the stock an “overweight” rating in a report on Friday, February 6th.

Encompass Health Trading Down 0.4%

Shares of EHC stock opened at $102.31 on Monday. Encompass Health has a 12-month low of $92.77 and a 12-month high of $127.99. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The firm’s 50 day moving average is $104.02 and its 200 day moving average is $108.47. The stock has a market capitalization of $10.17 billion, a P/E ratio of 18.47, a P/E/G ratio of 1.97 and a beta of 0.75.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 5th. The company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.17. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The company had revenue of $3.09 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter last year, the company posted $1.17 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Research analysts expect that Encompass Health will post 5.91 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Wednesday, April 1st were given a $0.19 dividend. The ex-dividend date was Wednesday, April 1st. This represents a $0.76 annualized dividend and a yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is presently 13.72%.

Insider Activity at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 150,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total value of $16,746,000.00. Following the transaction, the chief executive officer directly owned 377,070 shares in the company, valued at approximately $42,096,094.80. This trade represents a 28.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Treasurer Edmund Fay sold 11,937 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $107.00, for a total transaction of $1,277,259.00. Following the completion of the transaction, the treasurer owned 89,325 shares in the company, valued at $9,557,775. The trade was a 11.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its position in Encompass Health by 24.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after acquiring an additional 948,202 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Encompass Health by 3,059,159.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after buying an additional 3,793,358 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Encompass Health by 21.7% in the 4th quarter. Wellington Management Group LLP now owns 3,384,877 shares of the company’s stock worth $359,271,000 after buying an additional 603,472 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in Encompass Health by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,722,887 shares of the company’s stock worth $289,008,000 after buying an additional 581,812 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Encompass Health by 23.4% in the 3rd quarter. Alliancebernstein L.P. now owns 2,515,878 shares of the company’s stock worth $319,567,000 after buying an additional 476,564 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.